10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Letter to the Editor Regarding “Ticagrelor for Asian Patients With Acute Coronary Syndrome in Real-World Practice: A Systematic Review and Meta-analysis of Observational Studies.” The Benefit of Using Person-Year When the Follow-up Period Varies in a Meta-analysis

      letter
      ,
      Indian Heart Journal
      Elsevier

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sir, We read with great interest a meta-analysis published in the Indian Heart Journal “Ticagrelor for Asian patients with acute coronary syndrome in real-world practice: a systematic review and meta-analysis of observational studies”. 1 We would like to congratulate the authors for their study on the effectiveness of ticagrelor vs clopidogrel in patients with acute myocardial infarction, by considering the data from published observational studies. The study has definitely provided us with better evidence in this field. However, we had the following observations to make: 1. Of the six studies included by the authors in the meta-analysis, each study had a different follow-up period. Also, there is a variation in the follow-up period for different cohorts (ticagrelor vs clopidogrel) within the study. An example for this discrepancy is a study by Lee et al included in the meta-analysis, 2 in which clopidogrel cohort was recruited and followed up from 2012 to 2014, while the ticagrelor cohort was recruited and followed up from 2013 to 2014. This implies that the first patient recruited in the clopidogrel cohort was followed up for three years unless he had a event of interest, and the first recruit of the ticagrelor cohort was followed up for a total period of two years. By logic, incidence rate of events increases with increase in the duration of follow-up. To avoid such discrepancies, a better method is to use patient-year in the denominator, which is calculated by multiplying the number of cohort recruits with the year of follow-up. 3 The pooled odds ratio (OR) of major bleeding for ticagrelor vs clopidogrel considering patient-year in the denominator is 1.40 (95% confidence interval [CI]: 0.92–2.13, I2 = 51%, p = 0.11) (Fig. 1) as compared with the OR for major bleeding reported by authors of meta-analysis (OR = 1.11 [95% CI: 0.62–2.00, I2 = 75%, p = 0.73]. Fig. 1 Pooled odds ratio and 95% confidence intervals (CIs) for major bleeding (total cohort population expressed as person-year) using a random-effects model by the method of inverse variance and heterogeneity assessed with the I2 measure. Fig. 1 2. Though as a rule of thumb, test for publication bias is to be performed when the number of included studies is more than ten as the power of tests otherwise is too low to distinguish chance from real asymmetry, inclusion of funnel plot in the meta-analysis would help the reader in assessing for any publication or other biases with respect to each outcome. 4 (Fig. 2) Fig. 2 Funnel plot (major bleeding). Fig. 2 Source(s) of support Nil. Presentation at a meeting Nil. Conflict of interest None.

          Related collections

          Most cited references3

          • Record: found
          • Abstract: found
          • Article: not found

          Meta-analytic methods for pooling rates when follow-up duration varies: a case study

          Background Meta-analysis can be used to pool rate measures across studies, but challenges arise when follow-up duration varies. Our objective was to compare different statistical approaches for pooling count data of varying follow-up times in terms of estimates of effect, precision, and clinical interpretability. Methods We examined data from a published Cochrane Review of asthma self-management education in children. We selected two rate measures with the largest number of contributing studies: school absences and emergency room (ER) visits. We estimated fixed- and random-effects standardized weighted mean differences (SMD), stratified incidence rate differences (IRD), and stratified incidence rate ratios (IRR). We also fit Poisson regression models, which allowed for further adjustment for clustering by study. Results For both outcomes, all methods gave qualitatively similar estimates of effect in favor of the intervention. For school absences, SMD showed modest results in favor of the intervention (SMD -0.14, 95% CI -0.23 to -0.04). IRD implied that the intervention reduced school absences by 1.8 days per year (IRD -0.15 days/child-month, 95% CI -0.19 to -0.11), while IRR suggested a 14% reduction in absences (IRR 0.86, 95% CI 0.83 to 0.90). For ER visits, SMD showed a modest benefit in favor of the intervention (SMD -0.27, 95% CI: -0.45 to -0.09). IRD implied that the intervention reduced ER visits by 1 visit every 2 years (IRD -0.04 visits/child-month, 95% CI: -0.05 to -0.03), while IRR suggested a 34% reduction in ER visits (IRR 0.66, 95% CI 0.59 to 0.74). In Poisson models, adjustment for clustering lowered the precision of the estimates relative to stratified IRR results. For ER visits but not school absences, failure to incorporate study indicators resulted in a different estimate of effect (unadjusted IRR 0.77, 95% CI 0.59 to 0.99). Conclusions Choice of method among the ones presented had little effect on inference but affected the clinical interpretability of the findings. Incidence rate methods gave more clinically interpretable results than SMD. Poisson regression allowed for further adjustment for heterogeneity across studies. These data suggest that analysts who want to improve the clinical interpretability of their findings should consider incidence rate methods.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cardiovascular and Bleeding Risks in Acute Myocardial Infarction Newly Treated With Ticagrelor vs. Clopidogrel in Taiwan.

            There are few data on ticagrelor in Asian patients. This study evaluated clinical outcomes with ticagrelor and clopidogrel in Taiwanese patients with acute myocardial infarction (AMI).Methods and Results:We used the Taiwan National Health Insurance Research Database to identify 27,339 AMI patients aged ≥18 years between January 2012 and December 2014, and only patients who survived greater than or equal to 30 days after AMI and took dual antiplatelet therapy were included. Cohorts of ticagrelor and clopidogrel were matched 1:8, based on propensity score matching, to balance baseline covariates. The primary efficacy endpoints were death from any cause, AMI, or stroke. The safety endpoints consisted of major gastrointestinal bleeding or intracerebral hemorrhage. Following propensity matching, the primary efficacy endpoint rate was 22% lower in the ticagrelor group than in the clopidogrel group (10.6% and 16.2%, respectively; adjusted HR, 0.779; 95% CI: 0.684-0.887). The safety endpoint rate was similar between the ticagrelor and clopidogrel groups (3.2% and 4.1% respectively; adjusted HR, 0.731; 95% CI: 0.522-1.026).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Ticagrelor for Asian patients with acute coronary syndrome in real-world practice: A systematic review and meta-analysis of observational studies

              Objective We aimed to assess the efficacy and safety of ticagrelor compared to clopidogrel in Asian patients with acute coronary syndrome (ACS) in real-world practice. Methods PubMed, Web of Science and Scopus databases were searched systematically to obtain relevant Asian observational studies. Results The meta-analysis included six studies with 27959 participants. Compared with clopidogrel, ticagrelor was significantly beneficial in prevention of major adverse cardiac events (MACCEs) (OR=0.62; 95% CI: 0.46-0.83, I2=69%, p=0.001) mainly driven by reducing stroke (OR=0.62; 95% CI: 0.49-0.78, I2=0%, p<0.001). No differences were found between ticagrelor and clopidogrel in the risk of cardiovascular mortality (OR=0.66; 95% CI: 0.41-1.06, I2=0%, p=0.09), target vessel revascularization (OR=0.53; 95% CI: 0.21-1.35, I2=82%, p=0.18), major bleeding (OR=1.11; 95% CI: 0.62-2.00, I2=75%, p=0.73), and net adverse clinical and cerebral events (OR=0.76; 95% CI: 0.55-1.04, I2=78%, p=0.09). However, ticagrelor significantly increased the incidence of major/minor (OR=1.73; 95% CI: 1.36-2.21, I2=0%, p<0.001) and minor bleeding (OR=1.73; 95% CI: 1.29-2.32, I2=0%, p<0.001). Sensitivity analyses did not find consistent effect of ticagrelor on prevention of all-cause death and myocardial infarction. Conclusion This meta-analysis suggested that ticagrelor might reduce the risk of MACCEs mainly by reducing stroke in Asian patients with ACS without increasing the rates of major bleeding. Ticagrelor did not show a significant effect on other parts of MACCEs. Considerable increase in the risk of major/minor and minor bleeding was observed in ticagrelor compared with clopidogrel users. Further high-quality studies are required to support these findings.
                Bookmark

                Author and article information

                Contributors
                Journal
                Indian Heart J
                Indian Heart J
                Indian Heart Journal
                Elsevier
                0019-4832
                2213-3763
                Mar-Apr 2019
                19 April 2019
                : 71
                : 2
                : 176-177
                Affiliations
                [1]Department of Critical Care Medicine, St. John's Medical College Hospital, Bangalore, Karnataka, 560034, India
                Author notes
                [] Corresponding author. Department of Critical Care Medicine, St. John's Medical College Hospital Bangalore 560034, Karnataka, 560034, India. ashirvadmangalore@ 123456gmail.com
                Article
                S0019-4832(19)30105-1
                10.1016/j.ihj.2019.04.004
                6620417
                31280834
                ef630498-3801-44e4-8ab4-a12149ae023b
                © 2019 Cardiological Society of India. Published by Elsevier B.V.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 1 March 2019
                : 16 April 2019
                Categories
                Letter to the Editor

                Comments

                Comment on this article